Financial incentives tied to hypertension quality metrics modestly increase blood pressure remeasurement but have limited impact on overall blood pressure control rates.
Among patients with marginally elevated blood pressure, incentives can lead to selective remeasurement and documentation of control without corresponding medication intensification.
Reduced antihypertensive dose adjustments in marginally hypertensive patients correlate with increased risk of stroke and acute coronary syndrome hospitalizations over 1 year.
These findings raise critical considerations about unintended consequences of pay-for-performance models in chronic disease management.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
